1. Home
  2. LBRT vs CELC Comparison

LBRT vs CELC Comparison

Compare LBRT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Energy Inc.

LBRT

Liberty Energy Inc.

HOLD

Current Price

$19.83

Market Cap

3.9B

Sector

Energy

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$89.54

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBRT
CELC
Founded
2011
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Medical Specialities
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.3B
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
LBRT
CELC
Price
$19.83
$89.54
Analyst Decision
Buy
Strong Buy
Analyst Count
12
9
Target Price
$27.50
$112.56
AVG Volume (30 Days)
3.7M
1.6M
Earning Date
04-22-2026
05-13-2026
Dividend Yield
1.06%
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$4,006,116,000.00
N/A
Revenue This Year
$0.27
N/A
Revenue Next Year
$7.44
$720.19
P/E Ratio
$140.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.90
$34.30
52 Week High
$34.48
$151.02

Technical Indicators

Market Signals
Indicator
LBRT
CELC
Relative Strength Index (RSI) 42.86 39.88
Support Level $22.89 $83.77
Resistance Level $26.77 $117.54
Average True Range (ATR) 1.09 6.54
MACD 0.23 -1.39
Stochastic Oscillator 48.32 12.43

Price Performance

Historical Comparison
LBRT
CELC

About LBRT Liberty Energy Inc.

Liberty Energy Inc is a integrated energy services and technology company focused on providing hydraulic fracturing services and related technologies to onshore oil and natural gas exploration and production (E&P) companies. The Company offers customers with hydraulic fracturing services, together with complementary services including wireline services, proppant delivery solutions, field gas processing and treating, compressed natural gas (CNG) delivery, data analytics, related goods (including sand mine operations), and technologies to facilitate lower emission completions, thereby helping customers reduce emissions profile. The company provides services across USA and Canada.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: